⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386240 | 1.00 | — | — | |
| SCHEMBL4454386 | 1.00 | — | — | |
| SCHEMBL4820839 | 0.88 | — | — | |
| SCHEMBL4820847 | 0.88 | — | — | |
| SCHEMBL16928574 | 0.86 | — | — | |
| SCHEMBL15508041 | 0.86 | — | — | |
| SCHEMBL25899583 | 0.86 | — | — | |
| SCHEMBL839272 | 0.82 | TSHR (0.30) | — | |
| SCHEMBL13619245 | 0.82 | CA2 (0.31) | — | |
| SCHEMBL16322618 | 0.82 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117940438-A | Heterocyclic compounds as MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4103579-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2022-12-21 | — | — | EP | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801587-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-03-25 | — | — | US | disclosed |
| US-7001895-B2 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LABORATORIES (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| US-5149462-A | Used as ferroelectric liquid crystal | MITSUBISHI RAYON COMPANY LTD. (JP) | 1992-09-22 | — | — | US | disclosed |
| EP-0409066-A2 | Optically active compound for liquid crystal and its use | MITSUBISHI RAYON COMPANY, LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |